1-1 of 1
Grever R. Michael, MD
Close
Sort by
Journal Articles

A Phase I Trial of Subcutaneous (SQ) Dose-Escalated Alemtuzumab in Patients with T-Cell Lymphoproliferative Disorders (T-LPD).

Pierluigi Porcu, MD, Robert A. Baiocchi, MD, Thomas S. Lin, MD, PhD, Kristie A. Blum, MD, Patricia Curtis, RN, Grever R. Michael, MD, John C. Byrd, MD
Journal: Blood
Blood (2007) 110 (11): 3417.
https://doi.org/10.1182/blood.V110.11.3417.3417
Published: 2007